EverHint – EMA 10 + Price + MACD – Top 12 Signals for Aug 06, 2026
12 signals. Healthcare leads (6). price range $6-$533. 4 with insider selling.
What This Signal Is
Experimental strategy combining price crossing above EMA10 from below with MACD Line crossing above Signal Line from below. Both conditions must occur on the same day for a signal, providing double confirmation and higher-quality setups.
Entry Criteria:
- Buy: Price > EMA10 AND MACD line crosses above signal line
- Sell: Price < EMA10 AND MACD line crosses below signal line
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh signal: All conditions met on today's close
Holding period: 1-3 weeks | Risk level: Medium-High
Market Context
Equity markets are displaying a mild risk-off tone on August 6, 2026, with the major indices posting modest declines. The Dow Jones is leading the pullback at -0.85%, suggesting some rotation out of value and blue-chip names, while the Nasdaq holds up comparatively well at -0.05%, indicating that growth and technology sentiment remains relatively intact. This divergence points to selective selling rather than broad market deterioration, which can create cleaner trending conditions for momentum-based strategies like EMA/MACD crossover signals.
Volatility, as measured by the VIX at 15.29 and falling 3.29% on the day, remains well within a subdued range. Low and declining volatility generally compresses intraday price swings, which benefits trend-following signals by reducing false breakouts and whipsaw risk. For EMA-price and MACD-based strategies, this environment supports cleaner signal confirmation, as price action tends to be more directional and less erratic when volatility is contained below the 20 threshold.
The concentration of signals in the Healthcare sector aligns well with the current market backdrop. Healthcare tends to attract defensive capital flows when broader market sentiment softens, as reflected in the Dow's underperformance today. This sector rotation dynamic suggests institutional money may be repositioning toward more defensive exposures, lending fundamental support to the momentum signals being generated. Traders should remain attentive to whether this defensive rotation broadens or reverses as the session progresses.
🟢 Buy Signals (12 of 12 total)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | COKE | Coca-Cola Consolidated... | Consumer Defensive | $188.23 | — | $14.8B |
| 2 | EHC | Encompass Health Corpo... | Healthcare | $124.82 | — | $12.4B |
| 3 | GSK | GSK plc | Healthcare | $52.17 | — | $104.5B |
| 4 | INSM | Insmed Incorporated | Healthcare | $132.55 | -$701,147 | $28.7B |
| 5 | IOVA | Iovance Biotherapeutic... | Healthcare | $6.21 | — | $2.8B |
| 6 | LHX | L3Harris Technologies,... | Industrials | $289.53 | — | $53.9B |
| 7 | NOV | NOV Inc. | Energy | $19.90 | — | $7.1B |
| 8 | QCOM | QUALCOMM Incorporated | Technology | $160.39 | -$6,062 | $168.4B |
| 9 | SIMO | Silicon Motion Technol... | Technology | $267.43 | — | $9.0B |
| 10 | SRPT | Sarepta Therapeutics, ... | Healthcare | $16.78 | -$39,459,827 | $1.8B |
| 11 | TSEM | Tower Semiconductor Ltd. | Technology | $224.70 | — | $25.4B |
| 12 | UTHR | United Therapeutics Co... | Healthcare | $532.94 | -$23,930,088 | $22.6B |
Field Notes
Sector concentration: Healthcare (6), Technology (3), Consumer Defensive (1)
Insider selling: UTHR (United Therapeutics Corporation, -$23,930,088), SRPT (Sarepta Therapeutics, Inc., -$39,459,827), INSM (Insmed Incorporated, -$701,147)
Data coverage: 41.7% insider, 8.3% congressional, 0.0% earnings, 33.3% news
Peer Analysis
UTHR (United Therapeutics Corporation): Leads 5 peers: INCY ($118.38), GMAB ($29.83), RPRX ($57.26), DGX ($238.50), ZBH ($97.19)
SRPT (Sarepta Therapeutics, Inc.): Leads 5 peers: RXRX ($3.18), AGIO ($31.95), BEAM ($27.25), COGT ($41.80), DNLI ($24.73)
QCOM (QUALCOMM Incorporated): Leads 5 peers: AMAT ($527.48), LRCX ($305.77), ARM ($286.68), UBER ($70.47), KLAC ($193.22)
LHX (L3Harris Technologies, Inc.): Leads 5 peers: URI ($1162.66), AXON ($522.46), PCAR ($132.06), ROP ($397.08), HEI ($363.29)
TSEM (Tower Semiconductor Ltd.): Leads 5 peers: AMKR ($54.16), NVMI ($381.32), QRVO ($95.33), LSCC ($128.70), APPF ($194.11)
Congressional Activity
QCOM (QUALCOMM Incorporated) 🔴 Bearish
- 1 sale by 1 member
Recent Headlines
QCOM (QUALCOMM Incorporated)
- Qualcomm Could Be One AI Deal Away From A Major Re-Rating
SIMO (Silicon Motion Technology Corporation)
- Silicon Motion Unveils MonTitan™ SSD Reference Design Kit for AI Infrastructure at FMS 2026
SRPT (Sarepta Therapeutics, Inc.)
- Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
- Sarepta Therapeutics Q2 Earnings Call Highlights
- Sarepta Therapeutics Q2 Earnings Call Highlights
- Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript
- Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates
- Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics
- Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
TSEM (Tower Semiconductor Ltd.)
- Tower Semiconductor Ltd (TSEM) Stock Down 11.9% but Still Overvalued -- GF Score: 71/100
Vlad's Take
Today's signals: Strong sector concentration in Healthcare (6 signals) suggests sector-specific rotation. 4 signals showing insider selling warrant caution.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 If this added value to your research, consider liking, sharing, or subscribing. It genuinely helps.